AC Immune S.A. (ACIU)

$3.43 -0.09 (-2.56%)
Market Cap 337.38M
Revenue (ttm) 31.02M
Net Income (ttm) -57.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -186.46%
Debt to Equity Ratio 0.00
Volume 970,600
Avg Vol 806,322
Day's Range N/A - N/A
Shares Out 100.41M
Stochastic %K 58%
Beta 1.62
Analysts Strong Sell
Price Target $9.00

Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, confor...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 21 345 91 21
Fax: 41 21 345 91 20
Address:
Building B, EPFL Innovation Park, Lausanne, Switzerland
midas7576
midas7576 Jan. 7 at 4:16 AM
$ACIU - Will be the next $VTYX . They actually have a larger pipeline.
0 · Reply
midas7576
midas7576 Jan. 6 at 2:55 PM
$ACIU .
0 · Reply
midas7576
midas7576 Jan. 6 at 2:55 PM
$ACIU
0 · Reply
TheMFBearKillla
TheMFBearKillla Jan. 5 at 3:14 PM
$ACIU Bullish on $ACIU! Biotech play with healthcare value focus. Technical setup looks solid. 🚀
0 · Reply
midas7576
midas7576 Jan. 5 at 2:46 PM
$ACIU Paying over the offer for stock today!
0 · Reply
JanetBSmellin
JanetBSmellin Jan. 5 at 2:46 PM
$ACIU Was hoping for some kind of response last week. Appreciate it bulls. 🤬
0 · Reply
JanetBSmellin
JanetBSmellin Jan. 2 at 11:17 PM
$ACIU Hello?
0 · Reply
midas7576
midas7576 Jan. 2 at 9:00 PM
$ACIU Closed at day high .............. not seen that before.
0 · Reply
midas7576
midas7576 Jan. 2 at 7:26 PM
$ACIU The volume today will be in excess of 3 times the same date last year.
0 · Reply
JanetBSmellin
JanetBSmellin Jan. 2 at 5:35 PM
$ACIU
0 · Reply
Latest News on ACIU
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD

Dec 15, 2025, 2:50 PM EST - 22 days ago

AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD

AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's

Dec 11, 2025, 12:47 PM EST - 26 days ago

AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease

Dec 11, 2025, 7:00 AM EST - 26 days ago

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 4, 2025, 7:00 AM EST - 2 months ago

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine

Oct 24, 2025, 8:50 AM EDT - 2 months ago

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 5, 2025, 7:00 AM EDT - 5 months ago

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 7:00 AM EDT - 8 months ago

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

Apr 2, 2025, 6:00 AM EDT - 9 months ago

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

Mar 25, 2025, 7:00 AM EDT - 10 months ago

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

Mar 13, 2025, 7:00 AM EDT - 10 months ago

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

Nov 14, 2024, 10:32 AM EST - 1 year ago

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

Jul 31, 2024, 8:30 AM EDT - 1 year ago

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26, 2024, 3:10 PM EDT - 1 year ago

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease

Jul 25, 2024, 7:00 AM EDT - 1 year ago

AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

May 28, 2024, 7:00 AM EDT - 1 year ago

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

Alzheimer's vaccine licensing deal boosts AC Immune

May 13, 2024, 8:47 AM EDT - 1 year ago

Alzheimer's vaccine licensing deal boosts AC Immune

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 13, 2024, 6:05 AM EDT - 1 year ago

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

May 13, 2024, 6:00 AM EDT - 1 year ago

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

TAK

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Mar 14, 2024, 7:00 AM EDT - 1 year ago

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

Feb 22, 2024, 7:00 AM EST - 2 years ago

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

Jan 22, 2024, 7:00 AM EST - 2 years ago

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

Jan 3, 2024, 8:10 AM EST - 2 years ago

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts

Dec 18, 2023, 6:25 PM EST - 2 years ago

AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts

AC Immune Announces Pricing of Underwritten Offering of Common Shares

Dec 15, 2023, 7:56 AM EST - 2 years ago

AC Immune Announces Pricing of Underwritten Offering of Common Shares

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

Dec 15, 2023, 7:22 AM EST - 2 years ago

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

Dec 1, 2023, 7:00 AM EST - 2 years ago

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 2 years ago

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Nov 3, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

Nov 2, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

Oct 27, 2023, 7:00 AM EDT - 2 years ago

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

Oct 17, 2023, 7:00 AM EDT - 2 years ago

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

Oct 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

Sep 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aug 4, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

Jul 28, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

AC Immune SA Appoints New Chief Medical Officer

Jul 26, 2023, 7:00 AM EDT - 2 years ago

AC Immune SA Appoints New Chief Medical Officer

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

Jul 3, 2023, 7:00 AM EDT - 2 years ago

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

Jun 27, 2023, 7:52 AM EDT - 2 years ago

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

Jun 27, 2023, 7:00 AM EDT - 2 years ago

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

AC Immune Holds Annual General Meeting of Shareholders

Jun 23, 2023, 4:30 PM EDT - 2 years ago

AC Immune Holds Annual General Meeting of Shareholders

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Apr 28, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

Apr 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

Mar 20, 2023, 8:00 AM EDT - 3 years ago

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures

Mar 18, 2023, 9:00 AM EDT - 3 years ago

AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 16, 2023, 7:00 AM EDT - 3 years ago

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

Mar 8, 2023, 7:00 AM EST - 3 years ago

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

Feb 7, 2023, 7:00 AM EST - 3 years ago

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

AC Immune to Present at the SVB Securities Global Biopharma Conference

Feb 2, 2023, 8:15 AM EST - 3 years ago

AC Immune to Present at the SVB Securities Global Biopharma Conference

AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Jan 26, 2023, 7:00 AM EST - 3 years ago

AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease

Jan 18, 2023, 7:00 AM EST - 3 years ago

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease

midas7576
midas7576 Jan. 7 at 4:16 AM
$ACIU - Will be the next $VTYX . They actually have a larger pipeline.
0 · Reply
midas7576
midas7576 Jan. 6 at 2:55 PM
$ACIU .
0 · Reply
midas7576
midas7576 Jan. 6 at 2:55 PM
$ACIU
0 · Reply
TheMFBearKillla
TheMFBearKillla Jan. 5 at 3:14 PM
$ACIU Bullish on $ACIU! Biotech play with healthcare value focus. Technical setup looks solid. 🚀
0 · Reply
midas7576
midas7576 Jan. 5 at 2:46 PM
$ACIU Paying over the offer for stock today!
0 · Reply
JanetBSmellin
JanetBSmellin Jan. 5 at 2:46 PM
$ACIU Was hoping for some kind of response last week. Appreciate it bulls. 🤬
0 · Reply
JanetBSmellin
JanetBSmellin Jan. 2 at 11:17 PM
$ACIU Hello?
0 · Reply
midas7576
midas7576 Jan. 2 at 9:00 PM
$ACIU Closed at day high .............. not seen that before.
0 · Reply
midas7576
midas7576 Jan. 2 at 7:26 PM
$ACIU The volume today will be in excess of 3 times the same date last year.
0 · Reply
JanetBSmellin
JanetBSmellin Jan. 2 at 5:35 PM
$ACIU
0 · Reply
JanetBSmellin
JanetBSmellin Jan. 2 at 5:35 PM
$ACIU Phase 3 completion already estimated for March 2026???
0 · Reply
Awesom69Trade
Awesom69Trade Jan. 2 at 1:53 PM
$ACIU Prediction, will trade double digits in 2026!!
0 · Reply
BLD33
BLD33 Dec. 31 at 6:14 PM
$ACIU new all time high for 2026??
0 · Reply
midas7576
midas7576 Dec. 29 at 4:39 PM
$ACIU Updated! https://clinicaltrials.gov/study/NCT05641688
2 · Reply
Awesom69Trade
Awesom69Trade Dec. 29 at 2:37 PM
$ACIU nice volumes so far. This should be trading over $5+
1 · Reply
CalculusCharm
CalculusCharm Dec. 27 at 1:32 PM
$ACIU Investors are weighing durability against tactical noise; free‑cash‑flow conversion needs to normalize — any stumble could quickly widen valuation discounts. Until validation appears, volatility remains the default.
0 · Reply
RatioSectorNavigator
RatioSectorNavigator Dec. 27 at 8:02 AM
$ACIU Capital seems to prefer stability in metrics rather than volatile growth spurts. Balance‑sheet flexibility may prove significant. Sustained improvement may validate the long‑term thesis. Patience is warranted — but must be supported by results.
0 · Reply
AlphaTauri
AlphaTauri Dec. 18 at 4:58 AM
$ACIU i was monitoring this a few weeks. The dec 12th PR seems neutral at this point IMHO. PD is, like all neurodegenerative diseases, complex and I doubt that targeting misfolded Alpha-Syn is a disease changing strategy. The main cause of why dopamin cells are destroyed still remains unknown. Like Beta-Amyloid aggregation in AD, the treatment to clear them out was disapointing. I must delve further into the trial to see the duration of the follow up, if stabilization of symptoms after 1 year follow up, it could mean something. If it's just 6 months, i will take it with circonspection...
1 · Reply
Greencap
Greencap Dec. 18 at 12:00 AM
$ACIU pull the truck up
0 · Reply
Doru56
Doru56 Dec. 17 at 4:17 PM
$ACIU going back under $3.X ??
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 16 at 7:25 PM
$ACIU Share Price: $3.29 Contract Selected: May 15, 2026 $2.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.16 – $0.19 Potential Upside: 73% ROI Time to Expiration: 149 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Awesom69Trade
Awesom69Trade Dec. 12 at 11:22 PM
$ACIU Companh likely tapping into their ATM. They do it all the time and stock mostly give up all gains.
3 · Reply